Background There have been great advances in hepatocellular carcinoma management
over the last years. However, there are still no prognostic biomarkers that can identify …

Aim Immunotherapy in cancer is a recent and very promising approach, namely the
inhibition of the PD/programmed death-ligand 1 (PD-L1) axis. Here we aimed to investigate …

Background Blocking the programmed death protein 1 (PD-1)/programmed death-ligand 1
(PD-L1) pathway in hepatocellular carcinoma (HCC) is a very promising approach in …

Purpose To investigate the clinical implications of the soluble programmed cell death-ligand
1 (sPD-L1) level in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT) …

Background: The expression of programmed cell death ligands on tumor cells has a role in
the suppression of antitumor immunity, resulting in tumor immune evasion. Objective: In this …

Purpose Anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)
therapy has shown promise in tumor immunotherapy. Our objectives were to measure pre …

Background Preliminary studies have suggested that soluble programmed death-1 (sPD-1)
and soluble programmed cell death ligand-1 (sPD-L1) have prognostic implications in many …

Background Recent clinical studies have suggested that programmed death ligand 1 (PD-
L1) expression in a tumour could be a potential biomarker for PD-L1/PD-1 blockade …

Hepatocellular carcinoma (HCC) is the most common primary neoplasia of the liver. There
have been tremendous efforts in the development of therapeutic strategies in the last …

AIMS The present study aimed to determine the prognostic significance of soluble
Programmed Death-ligand 1 (sPD-L1) in hepatocellular carcinoma (HCC) patients …